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PEXPEDITED REVIEWS
Results of the U.S. Multicenter Pivotal Study
of the HELEX Septal Occluder for Percutaneous
Closure of Secundum Atrial Septal Defects
Thomas K. Jones, MD, FACC,* Larry A. Latson, MD, FACC,† Evan Zahn, MD, FACC,‡
Craig E. Fleishman, MD, FACC,§ Joth Jacobson, MS,¶ Robert Vincent, MD, FACC,
Kirk Kanter, MD, for the Multicenter Pivotal Study of the HELEX Septal Occluder Investigators
Seattle, Washington; Cleveland, Ohio; Miami and Orlando, Florida; Flagstaff, Arizona; and Atlanta, Georgia
Objectives This study sought to compare the safety and efficacy of the HELEX septal occluder (HSO) with surgical repair of
atrial septal defect (ASD).
Background The HSO is a low-profile, double-disk occluder device for percutaneous closure of secundum ASD.
Methods Patients were enrolled (HSO arm prospectively, surgery arm prospectively/retrospectively) from 14 U.S. sites and
followed up for 12 months postprocedure. Investigator-reported outcomes were evaluated, including closure suc-
cess (no or clinically insignificant residual shunt) and the incidence of adverse events. The first 3 HSO patients at
each site were considered training cases and were excluded from analysis.
Results Between March 2001 and April 2003, 119 nontraining cases received an HSO and 128 had surgical repair. The
groups were similar with statistical but clinically unimportant differences in median age, weight, and preproce-
dural echocardiographic defect size. Anesthesia time and hospital stay were significantly shorter in the HSO
group. Closure success, defined as complete closure or a clinically insignificant residual shunt, was similar in
both groups. Major and minor adverse events rates were not statistically different. The most common major ad-
verse events for the HSO group was device embolization requiring catheter retreival (1.7%), and in the surgery
group was postpericardiotomy syndrome (6.3%), including one death because of tamponade. The primary end
point, clinical success, a composite of closure success and no major adverse events at 12 months, satisfied the
noninferiority hypothesis comparing device closure with surgery.
Conclusions Closure of ASD with the HELEX septal occluder is safe and effective when compared with surgical repair, with
reduced anesthesia time and hospital stay. (U.S. Multicenter Pivotal Study of the HELEX Septal Occluder for Per-
cutaneous Closure of Secundum Atrial Septal Defects; this study was approved by the Food and Drug Adminis-
tration before the National Institutes of Health website was active, so there is not a URL or registration
number.) (J Am Coll Cardiol 2007;49:2215–21) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.053c
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Mecundum atrial septal defect (ASD) is a common congen-
tal cardiac anomaly accounting for approximately 10% of all
rom the *Children’s Heart Center, Children’s Hospital and Regional Medical
enter, Seattle, Washington; †Department of Pediatric Cardiology, Cleveland Clinic
oundation, Cleveland, Ohio; ‡The Congenital Heart Institute, Miami Children’s
ospital, Miami, Florida; §The Congenital Heart Institute, Arnold Palmer Chil-
ren’s Hospital, Orlando, Florida; ¶Gore Medical Products, W. L. Gore &
ssociates, Inc., Flagstaff, Arizona; and the Division of Cardiothoracic Surgery,
mory University School of Medicine, Atlanta, Georgia. The Multicenter Pivotal
tudy of the Helex Septal Occluder Investigators are listed in the Appendix. All of the
uthors participated as site investigators at their respective institutions, with the
xception of Mr. Jacobson, who is an employee of W. L. Gore & Associates, Inc. and
rovided statistical support. Additionally, Drs. Jones, Latson, and Zahn are consult-
nts to W. L. Gore & Associates, Inc., the manufacturer of the Helex Occluder and
he sponsor of this study.1
Manuscript received May 2, 2006; revised manuscript received November 13, 2006,
ccepted November 16, 2006.ongenital heart disease (1,2). It is one of the most common
ongenital heart defects to present in adulthood (3). Un-
reated, ASD produces right heart volume overload and
rogressive impairment over time, including reduced aero-
See page 2222
ic capacity, atrial dysrhythmias, congestive heart failure,
nd pulmonary hypertension (4–6). In the U.S. alone it is
stimated that approximately 10,000 new patients per year
an be expected to have an ASD. Successful surgical repair
f ASD has been performed for 50 years with continued
mprovement in technique and outcomes (7). King and
ills (8) reported the first transcatheter closure of ASD in
976, but the delivery system was quite large and imprac-
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HELEX Septal Occluder Pivotal Trial Results June 5, 2007:2215–21tical, especially for younger pa-
tients. With time, improvements
in design concepts and materials
discoveries have led to improved
results in transcatheter closure
systems (9). However, it has been
only recently that a transcatheter
SD closure device was deemed suitably effective and safe
o receive U.S. Food and Drug Administration approval for
arket release (10).
The HELEX septal occluder (HSO) (W. L. Gore &
ssociates, Flagstaff, Arizona) is a low-profile, double-disk
ccluder device designed to close secundum ASDs. The device
s composed of an expanded polytetrafluoroethylene mem-
rane bonded to a single nitinol wire frame and can be
elivered though a 9-F femoral venous sheath. The device is
ackaged with its integral delivery system (Fig. 1). Because it is
compliant, non–self-centering device, it is capable of con-
orming well to the curvilinear surfaces of the atrial septum.
he delivery system allows for repositioning or retrieval of the
evice after deployment. A safety cord attached to the device
rovides an additional level of patient safety by allowing for
emoval of the occluder even after device release. Previous
eports have shown the apparent safety of this device in initial
linical evaluations with high levels of clinical success (11–15).
ethods
tudy design. The HELEX Pivotal Study was a nonran-
omized, multicenter trial conducted in 14 medical centers
Figure 1 The HELEX Septal Occluder Is Shown Attached to the
By partially extending the mandrel within the control catheter, the left and right atr
Abbreviations
and Acronyms
ASD  atrial septal defect
HSO  HELEX septal
occludern the U.S. that evaluated the safety and effectiveness of the
SO in patients with ostium secundum ASD. The primary
bjective of the study was to show that the HSO was not
nferior to open heart surgical repair for the treatment of
stium secundum ASDs. Patients were enrolled prospec-
ively to receive the HSO and compared with surgical
atients enrolled both prospectively and retrospectively.
articipating centers and investigators with experience in
ranscatheter and surgical treatment of congenital heart
isease were selected. Individual investigators received stan-
ardized qualification and training including a series of
evice implantations performed in animal subjects before
articipation in the clinical trial. The study protocol was
pproved by each participating institution’s institutional
eview board, and informed consent was obtained from each
tudy participant.
Inclusion criteria for enrollment included the presence of an
stium secundum ASD and evidence of right heart volume
verload. Additional criteria for the device arm patients was a
alloon occlusion defect diameter22 mm and the presence of
dequate septal rims to secure the device as judged by the
ndividual investigator at the time of implantation. In the
urgical arm, patients could be enrolled retrospectively within
2 months of institutional review board approval.
Exclusion criteria for the study included the presence of
oncurrent cardiac defects requiring surgical repair or signifi-
ant comorbidities including a history of stroke, pulmonary
ypertension, pregnancy, or the presence of multiple ASDs
equiring the use of more than one device (device arm only).
gral Delivery System
ks of the occluder can be shown in this image.Inte
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June 5, 2007:2215–21 HELEX Septal Occluder Pivotal Trial ResultsSurgical repair of the ASD was carried out using accepted
tandard surgical techniques and individual surgical center
rotocols. For patients enrolled in the device arm, details of
he atrial septal anatomy were evaluated by either trans-
sophageal or intracardiac echocardiography at the time of
he cardiac catheterization procedure. At that time a final
etermination was made by the individual investigator
egarding the patient’s suitability for device implantation
ased on the inclusion criteria stated above.
Patients in each group were evaluated at 24 h, 4 weeks, 6
onths, and 12 months after treatment. Follow-up visits
ncluded a history and physical examination, electrocardio-
ram, and transthoracic echocardiogram. Additionally, for
atients enrolled in the device arm, fluoroscopy of the device
as performed at the 6- and 12-month follow-up visit.
utcome measures. The primary end point of the
ELEX Pivotal Study was clinical success, a composite of
afety and efficacy evaluated at 12 months postprocedure.
he criteria for clinical success were: 1) no major device or
rocedure adverse event through the 12-month follow-up;
) no repeat procedure to the target ASD; and 3) clinical
efect closure (complete occlusion or clinically insignificant
eak) at the 12-month follow-up. Secondary end points
valuated included the individual outcomes of safety and
fficacy. Safety outcomes for the study included assessment
f device-related and procedure-related adverse events
hrough the 12-month follow-up. Efficacy outcomes in-
luded assessment of defect closure at each of the follow-up
isits. Residual defect status was classified as: 1) complete
cclusion; 2) clinically insignificant leak with a small resid-
al shunt defined as a residual defect 3 mm and never 6
m accompanied by resolution of right ventricular enlarge-
ent and normalization of interventricular septal motion; or
) clinically significant leak.
tatistical analysis. The first 3 patients undergoing an
ttempt at device placement at each site were considered
raining cases and were excluded from the primary analyses
omparing outcomes with surgical controls. Subsequent
nalysis of the training cases identified no statistically
ignificant differences compared with nontraining cases in
atient characteristics or outcomes.
Baseline patient characteristics were compared between
evice nontraining and surgical control patients. Continu-
us measures were compared using the Wilcoxon rank sum
est. Categorical measures were compared by Fisher exact
est or chi-square test. The proportions of patients experi-
ncing one or more adverse events overall, and by subgroups
f interest, were compared using the Fisher exact test. The
roportions of patients achieving the primary end point,
linical success, were compared using a binomial propor-
ions test with a noninferiority margin of 10%. A value of p
0.05 was considered evidence of noninferiority. A pro-
ensity scores analysis was used to account for baseline
ifferences in patient populations. The SAS software (ver-
ion 8, SAS Institute Inc., Cary, North Carolina) was used
o perform all analyses.
eesults
total of 321 patients were enrolled in the study from 14
.S. sites between March 2001 and April 2003. The device
rm enrolled 50 training patients and 143 nontraining
atients, and the surgical control arm enrolled 128 patients.
urgical procedure dates ranged from January 2000 to
ecember 2002. Subsequent discussion of the data is
estricted to the 143 device nontraining and 128 surgical
ontrol patients.
Patient demographics are compared in Table 1, and
edical histories and current medications are compared in
able 2. On average, device patients were older with
omparatively smaller defects than surgical controls. These
tatistical differences served as the basis for the propensity
cores analysis.
Delivery of the HSO was attempted in 135 (94.4%) of the
43 enrolled device patients. The 8 patients with no delivery
ubject Demographics
Table 1 Subject Demographics
Device Non-Training Surgical Controls p Values*
Subjects enrolled 143 128
Gender
Male 49 (34.3%) 47 (36.7%) 0.704
Female 94 (65.7%) 81 (63.3%)
Subject ethnicity 0.898
White or
Caucasian
95 (66.4%) 84 (65.6%)
Black or African
American
15 (10.5%) 9 (7.0%)
Hispanic or
Latino
26 (18.2%) 23 (18.0%)
Asian 3 (2.1%) 7 (5.5%)
Other 3 (2.1%) 3 (2.3%)
Unknown 1 (0.7%) 2 (1.6%)
Subject age (yrs) 0.003
N 143 128
Mean (SD) 12.4 (14.0) 9.2 (12.2)
Median 6.5 4.7
Range (1.4, 72.4) (0.6, 70.4)
Weight (kg) 0.001
N 143 128
Mean (SD) 35.6 (26.0) 27.5 (22.4)
Median 23.0 17.5
Range (9.2, 132.5) (8.3, 135.0)
Body surface area 0.001
N 143 128
Mean (SD) 1.08 (0.51) 0.91 (0.46)
Median 0.89 0.72
Range (0.32, 2.61) (0.38, 2.01)
Estimated ASD
size (mm)
0.001
N 141 124
Mean (SD) 10.7 (3.8) 15.5 (6.3)
Median 10.0 15.0
Range (1.3, 25.0) (1.5, 42.0)
p values for continuous measures based on Wilcoxon test; for categorical variables on Fisher
xact test.
ASD  atrial septal defect.
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HELEX Septal Occluder Pivotal Trial Results June 5, 2007:2215–21ttempt were found during catheterization to have a balloon-
cclusion defect size 22 mm. Therefore, these patients were
xcluded per study eligibility criteria. Successful device delivery
as achieved in 119 (88.1%) of the 135 patients with delivery
ttempts. Device delivery was unsuccessful in 10 of the 16
atients because of the following anatomical considerations:
ultiple defects requiring more than one device, 2 patients;
nadequate defect rim, 1 patient; thin or floppy septum, 2
atients; impingement on cardiovascular structure, 1 patient;
ther characteristics (e.g., intracardiac dimensions too small
ompared to defect size) considered by the investigator to be
nappropriate for successful placement, 4 patients. In the 6
emaining patients, the investigator was unable to achieve
atisfactory device placement.
Procedural details of the 2 study groups are presented in
able 3. In the device group, the median balloon size of the
efect was 14 mm, compared with a resting median diam-
ter of 10 mm. The ratio of the balloon stretch to resting
iameter of 140% is consistent with previously published
eports and suggests that the investigators took care to avoid
verstretching the defect by observing the minimal balloon
iameter at which shunting ceased, referred to as the
stop-flow” diameter (16). The median fluoroscopic time of
2 min in the device group is typical for routine diagnostic
atheterizations performed in patients with congenital heart
isease and similar to the reported time for the only other
pproved atrial septal occluder device available in the U.S.
Subject Medical History
Table 2 Subject Medical History
Device No
Subjects enrolled 1
General medical history
Previous cardiac surgery 8 (5
ECG abnormalities 72 (5
Cardiac arrhythmia(s) 12 (8
Chromosomal abnormalities 4 (2
Emotional or psychiatric problems 5 (3
Epilepsy 0 (0
Failure to thrive 1 (0
Migraines 3 (2
Neurological deficits/symptoms 7 (4
Other (non-ASD) cardiac disease 15 (1
Other vascular disease 2 (1
Pre-term baby 6 (4
Respiratory difficulties 14 (9
Hepatitis 0 (0
Other 29 (2
Current medication
Antiarrhythmic 7 (4
Anticoagulant 2 (1
Antihypertensive 4 (2
Antiplatelet 10 (7
Diuretic 5 (3
Other 36 (2
*p values based on Fisher exact test. Only p values 0.1 displayed.
ASD  atrial septal defect; ECG  electrocardiographic.10). The duration of anesthesia time and of hospital stay pas also significantly less in the device group compared with
he surgical control group.
Major adverse events were reported in 5.9% of device
atients (7 of 119) and in 10.9% of surgical control patients (14
f 128) through the 12-month visit (Table 4). In the device
rm, removal of the device was required in 5 of the 7 patients.
wo patients experienced postprocedure device embolization
both within 24 h), 2 patients had device sizing issues that
equired removal (both on day 1), and 1 patient had a potential
ickel sensitivity that eventually resulted in device removal (day
29). The device was removed by percutaneous transcatheter
echnique in 5 of the 6 patients. The 1 patient with the
eported potential nickel sensitivity underwent surgical removal
nd defect closure at the request of his parents. Additionally, 1
atient experienced a procedure-related major adverse event of
etroperitoneal hemorrhage. The manipulation of an intracar-
iac echocardiogram catheter through tortuous iliac venous
natomy in this elderly anticoagulated patient was believed by
he investigator to have been the etiology of the bleeding event.
ne patient experienced a major adverse event with a potential,
ut not definite, relationship to the device or procedure. The
atient reported an acute, confusional migraine requiring
ospitalization on day 6 after implantation. Imaging studies
id not show any evidence of a cerebral embolic event, and the
omplaint resolved spontaneously. In the surgical control arm,
he major adverse event of pericardial effusion caused by
ning Surgical Controls p Values*
128
4 (3.1%)
89 (69.5%) 0.002
3 (2.3%) 0.034
7 (5.5%)
0 (0.0%) 0.062
0 (0.0%)
5 (3.9%)
1 (0.8%)
5 (3.9%)
5 (3.9%) 0.060
1 (0.8%)
8 (6.3%)
13 (10.2%)
0 (0.0%)
43 (33.6%)
2 (1.6%)
0 (0.0%)
2 (1.6%)
2 (1.6%) 0.038
5 (3.9%)
29 (22.7%)n-Trai
43
.6%)
0.3%)
.4%)
.8%)
.5%)
.0%)
.7%)
.1%)
.9%)
0.5%)
.4%)
.2%)
.8%)
.0%)
0.3%)
.9%)
.4%)
.8%)
.0%)
.5%)
5.2%)ostpericardiotomy syndrome requiring percutaneous drainage
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June 5, 2007:2215–21 HELEX Septal Occluder Pivotal Trial Resultsas reported in 8 patients, with pericardial tamponade con-
ributing to the death of 1 patient.
Minor adverse events were reported in 27.7% (33 of 119)
f device patients with a successful delivery and in 28.1% (36
Procedure Summary
Table 3 Procedure Summary
Device
Delivery attempted/surgery
Defect size by direct balloon sizing (mm)
N
Mean (SD)
Median
Range
Total time under fluoroscopy (min)
N
Mean (SD) 2
Median
Range (
Total time under anesthesia (min)
N
Mean (SD) 1
Median
Range (5
Days in hospital for procedure
N
Median
Range
*p Values for continuous measures based on Wilcoxon test; for categ
Number of Subjects by Category of Major AdverDelivery, or Surgical Closur Events Reported Th
Table 4 Number of Subjects by Category ofDelivery, or Surgical Closure Events
Subjects evaluable for safety
Subjects with 1 or more major adverse events
Cardiac
Bleeding (treatment required)
Embolization (post-procedure)
Pulmonary edema
Post-pericardiotomy syndrome
Integument
Allergic reaction
Neurologic
Migraine (new)
Paresthesia
Pulmonary (respiratory)
Stridor
Vascular
Hemorrhage (treatment or intervention required)
Wound
Hernia
Scarring or scar related
Device (HELEX septal occluder)
Allergic reaction
Device size inappropriate
Other
Anemia*p values based on Fisher exact test; †no subjects reported the event; ‡Na i
values are the total numbers of subjects in each category of adverse events.f 128) of surgical control patients through the 12-month
ollow-up period. In the device arm the most common
inor adverse events were arrhythmias (5.0%) and head-
ches (4.2%). Fractures in the wire frame of the device were
raining Surgical Controls p Values*
128
NA
NA
)
)
0.001
128
) 205 (43)
202
) (30, 330)
0.001
128
3
(1, 9)
ariables on Fisher exact test.
ents, Successful Deviceh 12-Month Follow-up
r Adverse Events, Successful Device
orted Through 12-Month Follow-up
Non-Training Surgical Controls p Value*
119 128
(5.9%) 14 (10.9%) 0.176
(1.7%) 10 (7.8%) 0.036
–† 1 (0.8%) 1.000
2 (1.7%) Na‡
– 1 (0.8%) 1.000
Na 8 (6.3%)
(0.8%) – 0.482
1 (0.8%) – 0.482
(1.7%) – 0.231
2 (1.7%) – 0.231
1 (0.8%) – 0.482
– 1 (0.8%) 1.000
– 1 (0.8%) 1.000
(0.8%) 1 (0.8%) 1.000
1 (0.8%) 1 (0.8%) 1.000
– 2 (1.6%) 0.499
– 1 (0.8%) 1.000
– 1 (0.8%) 1.000
(2.5%) Na
1 (0.8%) Na
2 (1.7%) Na
– 1 (0.8%) 1.000
– 1 (0.8%) 1.000Non-T
135
133
14 (4)
14
(5, 24)
134
8 (21
22
6, 148
133
68 (63
160
5, 360
135
1
(0, 4)se Evroug
Majo
Rep
Device
7
2
1
2
1
3ndicates that the event is not coded for that subject group. The bold
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HELEX Septal Occluder Pivotal Trial Results June 5, 2007:2215–21eported in 6 patients through the 12-month visit. None of
hese patients required intervention, and the Data Safety
onitoring Board adjudicated these as minor adverse events.
n the surgical control arm, the most common minor adverse
vents were postpericardiotomy syndrome not requiring hos-
italization (7.8%), followed by arrhythmias (3.9%), pericardial
ffusions (3.9%), and pneumopericardium (2.3%).
The residual defect status was determined on the 12-
onth echocardiogram by an independent echocardiogra-
hy core laboratory. Successful defect closure by either
ethod was defined by the study protocol as complete
losure or the presence of a clinically insignificant residual
efect. A clinically insignificant residual defect was further
efined as associated with normalization of right ventricular
olume and interventricular septal motion by transthoracic
chocardiography, and typically 3 mm and absolutely 6
m diameter as determined by color Doppler flow image.
f the 82 patients evaluated in the surgical control arm by
he core laboratory, 100% were determined to have success-
ul defect closure at 12 months postprocedure (Table 5). Of
he 105 patients evaluated in the device arm, 98.1% were
etermined to have successful defect closure on final evalu-
tion. Significant residual defects were identified in 1.9% (2
f 105) of device patients on final evaluation. Both of these
atients had multifenestrated defects that the investigator
elieved would be incorporated into the closure during the
ealing response over the first year. Neither of these patients
esidual Defect Status: Final Echo Core Lab Review
Table 5 Residual Defect Status: Final Echo Core Lab Review
Device Non-Training Surgical Controls
Subjects with successful delivery/
surgery
119 128
Subjects with core lab review 105 82
Completely occluded 77 (73.3%) 78 (95.1%)
Clinically insignificant leak 26 (24.8%) 4 (4.9%)
Clinically significant leak 2 (1.9%) 0 (0.0%)
Subjects missing core lab review 14 46
Discontinued study prior to
evaluation
6 (42.9%) 20 (43.5%)
Core lab review not completed 8 (57.1%) 26 (56.5%)
linical Success End Point
Table 6 Clinical Success End Point
Device Non-Tr
Evaluable subjects with successful delivery/surgical closure 117
Clinical success end point
Subjects evaluated 109
Clinical success 100 (91.7
Clinical failure 9 (8.3%
Major device/procedure adverse event‡ 7 (6.4%
Significant leak on final core lab evaluation 2 (1.8%
Subjects not evaluated 8
Lost to follow-up prior to evaluation 2
Final defect evaluation missing 6
Clinical success rate in surgical controls minus clinical success rate in HELEX non-training arm; †
vents.
CI  confidence interval.as noted to have wire frame fractures or any other
evice-related adverse events.
iscussion
he primary end point of the pivotal study was clinical success,
composite evaluation of safety and efficacy. The clinical
uccess end point was determined at 12 months postprocedure.
clinical success end point was determined only for patients
ith a successful device delivery or surgical closure and
ollow-up data on residual defect status and adverse events.
For the protocol-specified analysis, clinical success rates in
ligible patients were compared between nontraining device
nd surgical control patients. Clinical success was determined
n 109 of the 117 eligible device patients and in 86 of the 124
ligible surgical control patients (Table 6). Of the 46 patients
ot evaluated, 20 discontinued study follow-up without a
ajor adverse event and before final defect evaluation (2 device
atients, 18 surgical control patients), and 26 missed final core
aboratory evaluation of residual defect status (6 device patients,
0 surgical control patients). Clinical success was achieved in
1.7% (100 of 109) of device patients and in 83.7% (72 of 86)
f surgical control patients. Based on these data, the null
ypothesis of HSO inferiority was rejected in favor of the
oninferiority alternative hypothesis with p  0.001.
Differences in patient age, body size, estimated defect size
efore the procedure, and certain medical histories were
bserved between the 2 arms (Tables 1 and 2). A propensity
core analysis was conducted as a method to adjust for
actors that could confound the differences in clinical success
ates discussed above. The results show that the clinical
uccess rate for the HSO remains not inferior to surgical
losure when controlling for these baseline differences in
reatment arms (Table 7).
tudy limitations. This was not a randomized comparison
rial, nor would it be possible or appropriate in the current era
o conduct such a trial when alternative transcatheter closure
ethods are commercially available. However, every attempt
as made to conduct a contemporaneous comparison with
urgical closure within the same study institutions. Demo-
Surgical Controls Difference (90% CI)* p Value†
124
86
72 (83.7%) 8.0% (15.9%,0.2%) 0.001
14 (16.3%)
14 (16.3%)
0 (0.0%)
38
18
20
eriority binomial test p value with margin  0.10; ‡repeat procedures included as major adverseaining
%)
)
)
)
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June 5, 2007:2215–21 HELEX Septal Occluder Pivotal Trial Resultsraphic differences existed between the 2 groups but were
hown by a propensity score analysis to have no significant
mpact on the study results. The other limitation is the number
f surgical control patients lost to follow-up, with only 67% of
he enrolled control patients completing the 12 month evalu-
tions. However, site-reported outcomes of residual defect
tatus were reviewed for all patients who did not have a final
ore laboratory review. Six-month or 12-month site evalua-
ions were available for most device patients missing a final core
aboratory review. No clinically significant residual leaks were
eported in any of these device patients. Site-reported evalua-
ions for the surgical patients who missed final core laboratory
eview were available from the 12-month visit for 8 and from
he predischarge evaluation for all of the remaining patients. In
ll of these cases, the sites reported complete defect closure.
onclusions
his study shows that the HSO is a safe and effective
lternative for the transcatheter closure of secundum ASDs
ith a balloon occlusion diameter of 22 mm when
ompared with surgical closure. There is no statistical
ifference in clinical success between the two treatments. A
educed hospital stay and anesthesia time is associated with
he use of the HSO. Additionally, cardiac-related major
dverse events are less common with the use of the HSO,
rimarily because of the absence of significant postoperative
ericardial effusions seen in the surgical treatment group.
The choice of the most appropriate method for closure of
linically important ASD includes a number of issues that
elate to the compatibility of the device with specific patient
natomy. The compliant nature of the HELEX occluder
nd its non–self-centering construction are favorable design
eatures for certain anatomical forms of ASD. For larger
efects18 mm to 20 mm, alternative transcatheter devices
r surgical repair will still be required. However, greater
reedom of choice by the congenital interventional cardiol-
gists and their patients in the selection of devices for ASD
losure is now available.
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complete list is available in the Appendix. Special
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Table 7 Propensity Score Analysis: Clinical Success
Group
Surgical Clinical Success
N Clinical Success
First tertile 49 79.6%
Second tertile 21 95.2%
Third tertile 11 81.8%
Overall 81 85.5%
ropensity scores calculated using logistic regression model with all clinical covariates as predict
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APPENDIX
or a complete list of the participating institutes and investigators,
HELEX Clinical Success
Difference (90% CI)N Clinical Success
13 84.6% 5.0% (25.9%, 15.9%)
42 92.9% 2.4% (8.7%, 13.4%)
52 92.3% 10.5% (26.9%, 5.9%)
07 89.9% 4.4% (16.2%, 7.5%)
rall clinical success rates calculated as mean of tertile rates.1lease see the online version of this article.
